GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (MEX:NVS N) » Definitions » Cyclically Adjusted Book per Share

Novartis AG (MEX:NVS N) Cyclically Adjusted Book per Share : MXN512.30 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Novartis AG Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novartis AG's adjusted book value per share for the three months ended in Mar. 2024 was MXN322.708. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN512.30 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Novartis AG's average Cyclically Adjusted Book Growth Rate was -2.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 0.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novartis AG was 4.60% per year. The lowest was -0.70% per year. And the median was 3.45% per year.

As of today (2024-06-25), Novartis AG's current stock price is MXN1851.08. Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was MXN512.30. Novartis AG's Cyclically Adjusted PB Ratio of today is 3.61.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 3.50. The lowest was 2.23. And the median was 2.78.


Novartis AG Cyclically Adjusted Book per Share Historical Data

The historical data trend for Novartis AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Cyclically Adjusted Book per Share Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 539.77 581.45 602.17 598.50 576.18

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 514.39 534.67 500.65 576.18 512.30

Competitive Comparison of Novartis AG's Cyclically Adjusted Book per Share

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.



Novartis AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=322.708/107.3549*107.3549
=322.708

Current CPI (Mar. 2024) = 107.3549.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201406 376.292 101.517 397.932
201409 395.972 101.247 419.861
201412 435.164 100.704 463.905
201503 481.078 100.339 514.717
201506 511.686 100.464 546.785
201509 541.041 99.785 582.084
201512 558.074 99.386 602.819
201603 519.128 99.475 560.250
201606 562.727 100.088 603.585
201609 610.336 99.604 657.830
201612 649.862 99.380 702.015
201703 537.951 100.040 577.286
201706 539.441 100.285 577.469
201709 566.267 100.254 606.378
201712 628.543 100.213 673.338
201803 554.179 100.836 590.008
201806 650.089 101.435 688.028
201809 631.095 101.246 669.177
201812 667.881 100.906 710.565
201903 394.410 101.571 416.870
201906 431.037 102.044 453.471
201909 457.886 101.396 484.797
201912 461.914 101.063 490.671
202003 521.512 101.048 554.065
202006 542.641 100.743 578.255
202009 529.174 100.585 564.792
202012 498.865 100.241 534.270
202103 460.000 100.800 489.914
202106 480.950 101.352 509.435
202109 521.805 101.533 551.728
202112 620.990 101.776 655.033
202203 553.793 103.205 576.061
202206 579.957 104.783 594.193
202209 568.756 104.835 582.428
202212 545.823 104.666 559.844
202303 447.479 106.245 452.155
202306 429.762 106.576 432.905
202309 323.419 106.570 325.803
202312 387.537 106.461 390.790
202403 322.708 107.355 322.708

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Novartis AG  (MEX:NVS N) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1851.08/512.3
=3.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novartis AG was 3.50. The lowest was 2.23. And the median was 2.78.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novartis AG Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Novartis AG's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (MEX:NVS N) Business Description

Industry
Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (MEX:NVS N) Headlines

No Headlines